Hydrochlorothiazide
- Generic Name
- Hydrochlorothiazide
- Brand Names
- Accuretic, Actelsar Hct, Aldactazide, Altace HCT, Atacand, Atacand Hct, Avalide, Benicar Hct, Diovan Hct, Exforge Hct, Hyzaar, Ifirmacombi, Karvezide, Lopressor Hct, Lotensin Hct, Maxzide, Micardis-hct, Olmetec Plus, Tekturna Hct, Teveten HCT, Tribenzor, Urozide, Vaseretic, Viskazide, Zestoretic, Ziac
- Drug Type
- Small Molecule
- Chemical Formula
- C7H8ClN3O4S2
- CAS Number
- 58-93-5
- Unique Ingredient Identifier
- 0J48LPH2TH
- Background
Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension. Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and angiotensin converting enzyme inhibitors or angiotensin II receptor blockers.
Hydrochlorothiazide was granted FDA approval on 12 February 1959.
- Indication
Hydrochlorothiazide is indicated alone or in combination for the management of edema associated with congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis, chronic renal failure, and corticosteroid and estrogen therapy. Hydrochlorothiazide is also indicated alone or in combination for the management of hypertension.
- Associated Conditions
- Calcium Nephrolithiasis, Cirrhosis of the Liver, Congestive Heart Failure (CHF), Diabetes Insipidus, Edema, Hypertension, Hypertension, Essential Hypertension, Hypokalemia caused by diuretics, Nephrotic Syndrome, Pre-Eclampsia, Premenstrual tension with edema, Renal tubular acidosis, Sodium retention, Stroke
Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 Hypertension
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2011-08-12
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 812
- Registration Number
- NCT01415505
- Locations
- 🇺🇸
Forest Investigative Site 124, Muscle Shoals, Alabama, United States
🇺🇸Forest Investigative Site 135, Carmichael, California, United States
🇺🇸Forest Investigative Site 025, Los Angeles, California, United States
A Study of MK-7145 Compared to Placebo and Hydrochlorothiazide for Lowering Blood Pressure in Male Participants With Hypertension (MK-7145-009)
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2011-06-10
- Last Posted Date
- 2018-09-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 46
- Registration Number
- NCT01370655
Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age
- Conditions
- HypertensionChronic Kidney Disease
- Interventions
- First Posted Date
- 2011-06-03
- Last Posted Date
- 2016-07-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 150
- Registration Number
- NCT01365481
- Locations
- 🇸🇬
Novartis Investigative Site, Singapore, Singapore
To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy
- Conditions
- Non-diabetic Nephropathy
- Interventions
- First Posted Date
- 2011-02-24
- Last Posted Date
- 2013-01-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 8
- Registration Number
- NCT01302899
- Locations
- 🇳🇱
Novartis Investigative Site, Leeuwarden, Netherlands
Pharmacodynamics and Pharmacokinetics of Empagliflozin and Torasemide in Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2011-01-13
- Last Posted Date
- 2014-09-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 23
- Registration Number
- NCT01276288
- Locations
- 🇩🇪
1245.42.1 Boehringer Ingelheim Investigational Site, Neuss, Germany
A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People
- Conditions
- Cardiovascular Events
- Interventions
- First Posted Date
- 2010-12-14
- Last Posted Date
- 2014-04-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2336
- Registration Number
- NCT01259297
- Locations
- 🇸🇪
Novartis Investigative Site, Stockholm, Sweden
Hypertensive Ambulatory Trial to Compare the Efficacy of HCTZ and Lisinopril
- Conditions
- Hypertension, Grade 1Hypertension TreatmentN of 1 Study DesignHypertension
- Interventions
- First Posted Date
- 2010-12-13
- Last Posted Date
- 2015-05-20
- Lead Sponsor
- Scripps Translational Science Institute
- Target Recruit Count
- 2
- Registration Number
- NCT01258764
- Locations
- 🇺🇸
Scripps Clinic, La Jolla, California, United States
A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential Hypertension
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2010-12-08
- Last Posted Date
- 2015-10-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 341
- Registration Number
- NCT01256411
- Locations
- 🇹🇭
Novartis Investigative Site, Chiang Mai, Thailand
Pharmacokinetic Drug Interactions Between Single and Concomitant Administrations of Amlodipine, Losartan, and Hydrochlorothiazide in Subjects With (Pre)Hypertension
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2010-09-10
- Last Posted Date
- 2011-03-28
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 23
- Registration Number
- NCT01198249
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
Telmisartan, Amlodipine and Flow Mediated Dilation
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2010-08-12
- Last Posted Date
- 2011-07-12
- Lead Sponsor
- Johannes Gutenberg University Mainz
- Target Recruit Count
- 576
- Registration Number
- NCT01180205
- Locations
- 🇩🇪
Universitätsmedizin Mainz, Mainz, Rheinland-Pfalz, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.